Compare Raymond James Financial, Inc. (RJF) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs ResMed Inc. — how do they compare? Raymond James Financial, Inc. trades at $167 (market cap $32.73B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays the higher dividend (1.29%). Which is the better fit depends on your goals.
| RJF | RMD | |
|---|---|---|
Market Cap | $32.73B | $28.40B |
Sector | Financials | Health |
52-Week High | $176.43 | $293.73 |
52-Week Low | $140.89 | $182.82 |
Dividend Yield | 1.29% | 1.23% |
Enterprise Value | — | $27.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $167.93, down 0.26% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows strong fundamental performance with 2025 revenue of $13.84B and net income of $2.14B, supported by a P/E of 15.89. Analyst consensus is positive with a $176.83 price target, and recent news highlights advisor recruitment driving growth.
The outlook for RJF remains favorable due to earnings momentum and institutional interest, though risks include expense pressures and market volatility. The stock presents a growth opportunity with solid valuation support, but investors should monitor cost management and macroeconomic factors that could impact financial services performance.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
